Final overall survival: Fulvestrant 500 mg vs 250 mg in the randomized confirm trial

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Leo, Angelo Di ^a   Jerusalem, Guy ^b   Petruzelka, Lubos ^c   Torres, Roberto ^d   Bondarenko, Igor N ^e   Khasanov, Rustem ^f   Verhoeven, Didier ^g   Pedrini, José L ^h   Smirnova, Iya ⁱ   Lichinitser, Mikhail R ^j   Pendergrass, Kelly ^k   Malorni, Luca ^a   Garnett, Sally ^l   Rukazenkov, Yuri ^l   Martin, Miguel ^m  

^a HOSPITAL OF PRATO   (Italy)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Institute Nacional del Cáncer   (Chile)

^e Municipal Clinical Hospital 4   (Ukraine)

^f Republican Clinical Oncological Dispensary   (Russian Federation)

^g Algemeen Ziekenhuis Klina   (Belgium)

^h HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

ⁱ Medical Radiology Reseach Center   (Russian Federation)

^j N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^k Kansas City Cancer Center   (United States)

^l ASTRAZENECA   (United Kingdom)

^m UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; BREAST METASTASIS; BRONCHITIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FEMUR FRACTURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTESTINE CARCINOMA; MAJOR CLINICAL STUDY; MENINGITIS; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDE; TREATMENT RESPONSE; VOMITING; AGED; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RISK;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; ODDS RATIO; RECEPTORS, ESTROGEN;

EID: 84892648688     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt337     Document Type: Article

References (18)

1. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396-3403.
2. Cano A, Matallin P, Legua V, Tortajada M, Bonilla-Musoles F. Tamoxifen and the uterus and endometrium. Lancet. 1989;1(8634):376
3. Ewer MS, Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115(9):1813-1826.
4. Santen RJ. Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab. 2011;96(2):308-319.
5. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386-3395.
6. DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994;54(2):408-414.
7. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the shortterm biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)- nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61(18):6739-6746.
8. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer. 2002;87(12):1354-1359.
9. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-4600.
10. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98(2):229-238.
11. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530-4535.
12. Robertson JF, Lindemann J, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat. 2012;136(2):503-511.
13. Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435-444.
14. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized Phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30(16):1919-1925.
15. Di Leo A, Malorni L. Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. J Clin Oncol. 2012;30(16):1897-1900.
16. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
17. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):1950-1954.
18. Robertson JFR. Fulvestrant (Faslodex)-how to make a good drug better. Oncologist. 2007;12(7):774-784.